Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease.

Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease. Abstract Text:

Two tests of spatial-rotation ability were administered to 17 young normals, 23 aged normals, and 51 patients with diagnoses of Alzheimer's disease (AD). The AD patients consisted of 28 early dementia patients and 23 advanced dementia patients. On a computerized version of the Boston Naming Test, 40 objects were presented for naming, 20 of which were rotated 180 degrees. The subjects' capacity for mental rotation was assessed on the basis of their accuracy of naming of rotated vs. unrotated objects. On Money's Standardized Road Map Test, in which the subject is asked whether turns on a map are to the left or to the right, spatial-rotation ability was assessed on the basis of the subject's left-right orientation on turns with movement away from the subject (requiring no rotation) vs. turns with movement toward the subject (requiring rotation). Performance on both tasks was progressively worse in the young normal, aged normal, early dementia, and advanced dementia groups. Both tasks demonstrated a clear spatial-rotation deficit in the elderly. Although the spatial-rotation effect was superimposed upon deficits in naming and left-right orientation in the demented subjects, the magnitude of the rotation effect did not significantly differ in the aged normal vs. the early dementia group on either task, suggesting that early AD produces no further impairment of spatial-rotation abilities than is produced by normal aging.

Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease. Publishing Authors By Initials

For similar psychological phenomena and processes: mental processes: perception: space perception research abstracts see: psychological phenomena and processes: mental processes: perception: space perception research

PUBMED ID PMID:

MEDLINE DATE:

Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Journal of clinical and experimental neuropsycholo

VOLUME: 10

Page Numbers: 387-99

Journal Abbreviation:

ISSN: 1380-3395

DAY: 14

MONTH: Aug

YEAR: 1988

Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8502170

Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease. Keywords Mesh Terms:

KEYWORDS: Space Perception

MESH TERMS: physiology

Chemical & Substance for Abstract: Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease.

AFFILIATION: Dept. Psychiatry, NYU Medical Center, NY 10016.

Country: NETHERLANDS

AGENCY: United States NIMH

GRANT: MH40410

ACRONYM: MH

MEDLINETA: J Clin Exp Neuropsychol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease Related Publications

• A visual recognition memory test for the assessment of cognitive function in aging and dementia.
• Age differences in the vulnerability of facial recognition memory to proactive interference.
• Age-related differences in behavior across the life span of the C57BL/6J mouse.
• Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease.
• Four stimulants of the central nervous system: effects on short-term memory in young versus aged monkeys.
• Pseudoaneurysm of the inferior epigastric artery: diagnosis and percutaneous treatment.
• Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
• Striatal Delivery of Neurturin by CERE-120, an AAV2 Vector for the Treatment of Dopaminergic Neuron Degeneration in Parkinson's Disease.
• Therapeutic potential of CERE-110 (AAV2-NGF): Targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons.
• Transgene Expression, Bioactivity, and Safety of CERE-120 (AAV2-Neurturin) Following Delivery to the Monkey Striatum.
• Ultrastructure of immediate microvascular lung injury induced by bacterial endotoxin in the isolated, no-deficient lung perfused with full blood.